Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2016 Oct 7;15(12):2936–2945. doi: 10.1158/1535-7163.MCT-16-0354

Figure 3. The binding of VPC-13566 to the BF3 pocket of AR.

Figure 3

A- BLI dose-response curves (5–50 μM) reflecting the direct binding of the VPC-13566 to the purified ligand binding domain of AR. The specific binding to the BF3 site was confirmed by the decrease of the endogenous AR/BAG1L interaction in LNCaP cells as seen by proximity ligation assay (B–D). Statistical significance was set at P < 0.01 (**) and P < 0.001 (***).